Cytokines as Immunological Markers for Follow up of Disease Activity During the Treatment of Pulmonary Tuberculosis

Authors

  • Ahmed Bolad Al Neelain University, Faculty of Medicine,Department of Microbiology
  • Amal Elhaj Al Neelain University, Faculty of Medicine,Department of Microbiology
  • Atif Elagib Sudan Academy of Science-Tropical Medicine Institute

DOI:

https://doi.org/10.52981/sjms.v7i4.856

Keywords:

Tuberculosis, Cytokines, Immunological markers

Abstract

Background: Cytokines play a major role in protection against Mycobacterium tuberculosis infection and regulate the immune responses at a cellular level. Cytokine profile determines clinical outcome of the disease and responses to treatment as well. A T helper 1 (Th1) cytokine interferon gamma (IFN-U) is one of the most important cytokines which activate the macrophages to produce tumor necrosis factor-alpha (TNF-V). Excessive production of TNF-V have been implicated in immunopathogenesis of tuberculosis. A T helper 2 (Th2) response leads to release of IL-4, and IL-10 promoting an anti-inflammatory macrophage response. Interleukin-4(IL-4), has been implicated to down-regulate IFN-U, and thus has a harmful effect on TB patients. IL10 cytokine has the
capacity to inhibit Th1 activation and thus terminates cell mediated immune responses.
Objective:The objective of the present study was to determine Th1 and Th2 cytokine profile in patients with tuberculosis to identify immunological marker for follow up of the disease activity, and to study the outcome of treatment.
Methods: To examine this, blood samples were collected from newly diagnosed HIV negative pulmonary tuberculosis patients and from apparently healthy individuals as controls following an informed consent. Blood samples were as well collected at several intervals during the treatment with anti-tuberculosis drugs. Levels of IFN-U, TNF-V, IL-4 and IL-10 were measured pre and during treatment using commercial available enzyme-linked immune-sorbent assay (ELISA). Data were analyzed using SPSS 20. Receiver Operating Characteristic (ROC) Curve analysis has been
carried out to assess their discriminative power and to determine cut-off values. Analysis has been carried out further by calculating other measures of diagnostic test accuracy.
Results: The median serum level of IL-4 was 20 and 35 pg/ml higher in new cases (untreated patients) and in patients under treatment with oral anti-tuberculosis, respectively, compared with that of controls (p=001). Levels of TNF- were significantly increased in patients before and after
the treatment than those in control (p=0.001). New cases had the highest median level (10pg/ml) followed by those under treatment group (6pg/ml). Levels for IFN-U were not statistically different between patients and controls (p=0.351). Median levels of IL10 were similar in both controls and new cases groups (35pg/ml), but lower in patients under treatment group (20pg/ml). Increase in levels of IL-4 during treatment showed that Th2 immune responses still present and may indicate active disease and thus IL4 cytokine may be a possible marker for the disease activity.
Conclusion: serum levels of TNF- in TB patients is useful in the evaluation of the disease activity during therapy, not replacing clinical parameters of disease activity in TB. Similar to TNF-, IL-4 can also be used as marker for TB severity. On the other hand IL-4test can be used to diagnose TB
in highly exposed suspects where a positive result is more likely to indicate TB.

References

1. Prsco TT. Harl EX Klein. 1999, Microbiology, fourth edition Colorado state university.
2. World Health Organization , Global Tuberculosis Control, WHO; 2011.
3. Janis E. Wigginton and Denise Kirschner, A model to predict cell-Mediated Immune Regulatory Mechanisms During Human Infection With Mycobacterium tuberculosis, J. Immunology, 2001;166:1951-1967.
4. van Crevel R, Karyadi E, Preyers F, Leenders M, Kullberg BJ, Nelwan RH, van der Meer JW. Increased production of Interlukine-4 by CD4+and CD+8 T cells from patients with tuberculosis is related to the presence of pulmonary cavities. J. Infect. Dis. 2000;181:1194-1197.
5. Octavio M. Rivero-Lezcano, Cytokines as Immunomo dulators in Tuberculosis Therapy, 2008;3:168-176
6. Bai Y., Xue Y., Gao H., etal., Expression and purification of Mycobacterium tuberculosis ESAT-6 MpT64 fusion protien and its immunoprophylatic potential in mouse modle. Protein Expression and purification 2008;59:189- 196.
7. Ludovic Desvignes , Joel D. Ernst, Interferon-UResponsive Nonhematopoietic Cells Regulate the Immune Response to Mycobacterium tuberculosis, J. Immun. 2009;31:974-985.
8. Poveda F., Camacho J., Arnalich F. , Codoceo R. delArco A., Partinez-Henandez P.., Circulating cytokine concenttrations in Tuberculosis and other chronic Bacterial Infections, Infection 27 4/5 ©URBAN &VOGEL. springer, 1999;27:272-274.
9. Keertan Dhed, Jung-Su chang, Ronan A. M. Breen, etal., In vivo and invitro Studies of novel cytokine, interluken 4] in pulmonary Tuberculosis. American J .Resp. &critical care Medicine. 2005;172:501-508.
10. Neil W., Schucer and Willam N. ROM. The Host Immune Response to tuberculosis .Am J. Respir. Care Med., 1998;157:679-691.
11. Levent Kart, Hakan Buyukoglan, Ishak O Tekin, Remzi Altin, Zuhal Senturk, Inci Gulmez, Ramazan Demir, and Mustafa Ozesmi, Correlation of serum tumor necrosis factor-alpha, interleukin-4 and soluble interleukin-2 receptor levels with radiologic and clinical manifestations in active pulmonary tuberculosis. Mediators of Inflammation, 2003;12:9-14
12. Dahir Ramos de Andrade Júnior, Sânia Alves dos Santos, Isac de Castro and Dahir Ramos de Andrade, Correlation Between Serum Tumor Necrosis Factor Alpha Levels and Clinical Severity of Tuberculosis, Brazilian Journal of Infectious Diseases, 2008;12:226-233.
13. MMWR Morb Mortal Wkly Rep. Tuberculosis Associated with Blocking Agents Against Tumor Necrosis Factor-Alpha, California, 2002–2003. Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report 2004;53: 683-686.
14. Turner J, Gonzalez-Juarrero M, Ellis DL etal, In vivo IL-10 production reactivates chronic pulmonary tuberculosis in C57BL/6 mice. J Immunol. 2002;1;169(11):6343-6351.
15. Thillai M, Eberhardt C, Lewin AM, Potiphar L, Hingley-Wilson S, Sridhar S, Macintyre J, Kon OM, Wickremasinghe M, Wells A, Weeks ME, Mitchell D, Lalvani A. July 16, 2012, Sarcoidosis and Tuberculosis Cytokine Profiles: Indistinguishable in Bronchoalveolar Lavage but Different in Blood, . PLoS One. 2012;7(7).
16. Wing Wai Yew and Chi Chiu Leung Pulmonary and Critical Care Updates in Tuberculosis 2005, China, Am J Respir Crit Care Med 2006;173:491– 498.
17. Rogelio Hernández-Pando,1 Diana Aguilar,1 Hector Orozco,1 Yuriria Cortez,1 Laura Rosa Brunet,2 and Graham A. Rook3, Orally Administered Mycobacterium vaccae Modulates Expression of Immunoregulatory Molecules in BALB/c Mice with Pulmonary Tuberculosis Clin Vaccine Immunol. 2008; 15: 1730–1736.
18. Sahiratmadja E, Alisjahbana B, de Boer T, Adnan I, Maya A, Danusantoso H, et al., Dynamic changes in pro- and anti-inflammatory cytokine profiles and gamma interferon receptor signaling integrity correlate with tuberculosis disease activity and response to curative treatment. Infect Immun. 2007;75:820-829.
19. Moura EP, Toledo VP, Oliveira MH, Spíndola-deMiranda S, Andrade HM, Guimarães TM. May 2004 Pulmonary tuberculosis: evaluation of interferon- levels as an immunological healing marker based on the response to the Bacillus Calmette-Guerin; Mem Inst Oswaldo Cruz. 2004;99:283-287.
20. Hirsch CS, Toossi Z, Vanham G, et al. Apoptosis and T-cell hyporesponsiveness in pulmonary tuberculosis. J Infect Dis. 1999;179:945–953.
21. Keane J, Remold HG & Kornfeld H. Virulent Mycobacterium tuberculosis strains evade apoptosis of infected alveolar macrophages. J Immunol. 2000;164: 2016-2020.
22. Hirsch CS, Toossi Z, Othieno C, Johnson JL, Schwander SK, Robertson S, Wallis RS, Edmonds K, Okwera A, Mugerwa R, Peters P, Ellner JJ. Depressed T-Cell Interferon-g Responses in Pulmonary Tuberculosis: Analysis of Underlying Mechanisms and Modulation with Therapy Journal of Infectious Diseases1999;180:2069–2073.
23. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001;19: 93-129.

Downloads

Published

2021-08-11

Issue

Section

Original Articles